How long does it take for mivamutin injection to take effect?

Mifamurtide is an immunomodulator that is widely used in the adjuvant treatment of patients with high-grade, non-metastatic osteosarcoma, especially after tumor resection and standardized chemotherapy. Its main mechanism of action is to activate the body's monocyte-macrophage system to eliminate remaining tumor cells by enhancing the host immune response, thereby reducing the risk of recurrence and prolonging disease-free survival. Because it is not a chemotherapy drug that directly kills tumor cells, but indirectly exerts an anti-tumor effect by mobilizing the body's immune mechanism, its onset of action may be slightly delayed compared to traditional drugs.

Generally speaking, the effect of mivamutide is not immediate. Based on overseas treatment experience, the clinically recommended period of use ranges from 12 weeks to 36 weeks, with injections twice a week, and then once a week until the complete course of treatment is completed. The cumulative use time can reach about 6 months. During this process, the patient's immune system is gradually activated, especially the function of macrophages, which is continuously mobilized to ultimately eliminate residual tumor cells. Although some patients may experience faster physical recovery or stable improvement in symptoms within a few weeks, the true anti-tumor effect of immunotherapy generally needs to be evaluated through imaging, laboratory tests, etc. in the middle and late stages of treatment, especially after the entire treatment cycle is completed before comprehensive judgment is made.

It should be emphasized that the effect of mivamutide is affected by many factors, including the patient's age, basic immune status, thoroughness of surgery, combined chemotherapy regimen, and individual differences. Therefore, the question of when the effect will be effective cannot be determined based on specific days or weeks, but should be evaluated based on the full course of treatment management. If symptoms such as fever, chills, fatigue, etc. occur during use, it is one of the manifestations of the drug activating the immune system. Patients do not need to worry too much, but it is still recommended to continue observation under the guidance of a professional doctor.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact